WEIFANG, Shandong, China, Aug. 4 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has retained Grayling Global to lead a strategic communications program ("the IR program") to shareholders, the investment community and financial media.
As the investor relations counsel for Shengtai Pharmaceutical, Grayling Global will help raise the investment community's awareness of the Company's performance through timely corporate updates, direct communications with fund managers, financial media placements and investor conference presentations. "We are pleased to have a global IR network and its senior counselors with long standing healthcare and industrial track records to help us raise our financial profile and ensure the full understanding of our business model and exciting growth prospects," said Mr. Qingtai Liu, Chief Executive Officer of Shengtai Pharmaceutical. "We need to increase our visibility and expand our relationships with U.S. investors. As we are becoming a bigger company and planning to move onto main exchange, we believe Grayling Global is best suited to guide this investor relations process."
Grayling Global, a subsidiary of Huntsworth PLC (LSE: HNT), is headquartered in London, with offices in New York, Brussels, Bangkok, Singapore, Madrid, Moscow, Tel Aviv, Hong Kong, Istanbul, Los Angeles, Sacramento, Dublin, Edinburgh, Cardiff, Bristol, and Birmingham. The firm has over 200 consultants, focusing on first-class delivery in public affairs, public relations, investor relations and events management.
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes, and the glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: Certain statements in this press release and oral statements
made by the Company constitute forward-looking statements for purposes of
the safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. These statements include, without limitation, statements
regarding our ability to prepare the company for growth, the Company's
planned capacity expansion in 2008 and predictions and guidance relating to
the Company's future financial performance. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we believe may
affect our financial condition, results of operations, business strategy
and financial needs but they involve risks and uncertainties that could
cause actual results to differ materially from those in the forward-looking
statements, which may include, but are not limited to, such factors as
unanticipated changes in product demand especially in the pharmaceutical
industry, pricing and demand trends for the Company's products, changes to
government regulations, risk associated with operation of the Company's new
facilities, risk associated with large scale implementation of the
company's business plan, the ability to attract new customers, ability to
increase its product's applications, cost of raw materials, downturns in
the Chinese economy, and other information detailed from time to time in
the Company's filings and future filings with the United States Securities
and Exchange Commission. Investors are urged to consider these factors
carefully in evaluating the forward-looking statements herein and are
cautioned not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement. The
forward-looking statements made herein speak only as of the date of this
press release and the Company undertakes no duty to update any
forward-looking statement to conform the statement to actual results or
changes in the company's expectations.
For more information, please contact:
Shengtai Pharmaceutical, Inc.
Ms. Melody Shi
Chief Financial Officer
|SOURCE Shengtai Pharmaceutical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved